文献速递胸部CT

直方图分析对铂类难治性非小细胞肺癌接受纳武利尤单抗治疗患者的预后与预测价值:一项多中心回顾性研究

Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study.
PubMed 文献 · Eur J Radiol · 2019-07-17

该多中心回顾性研究纳入104例铂类难治性非小细胞肺癌患者,采用TexRAD软件在CT上提取直方图特征,用LASSO筛选与总生存和无进展生存相关的特征。结果显示SSF=4mm的峰度与总生存相关(HR 0.476,95%CI 0.29-0.77),SSF=6mm的峰度与无进展生存相关(HR 0.556,95%CI 0.36-0.86)。作者认为CT直方图分析可能有助于接受纳武利尤单抗治疗患者的预后分层和治疗反应评估。

要点

  • CT直方图分析中SSF=4mm的峰度与总生存相关,HR为0.476(95%CI 0.29-0.77)。
  • SSF=6mm的峰度与无进展生存相关,HR为0.556(95%CI 0.36-0.86)。
  • 该研究为多中心回顾性设计,中位随访13.8周,中位总生存7.3个月、中位无进展生存3个月。

核心结论

  • 尽管存在局限性,本研究首次提示CT直方图分析可能在接受纳武利尤单抗治疗的NSCLC患者预后分层和治疗反应评估中发挥作用。

研究设计与样本

  • 多中心回顾性研究,纳入3个中心的104例铂类难治性非小细胞肺癌患者,CT扫描在不同扫描仪上采用相似参数,使用TexRAD软件提取不同空间尺度滤波(SSF)的直方图特征,每位患者产生30个CT直方图分析特征,采用交叉验证的最小绝对收缩和选择算子(LASSO)筛选与总生存和无进展生存相关的特征。

关键影像表现/征象

  • CT直方图分析在SSF=4mm时提取的峰度是唯一与总生存相关的特征。
  • CT直方图分析在SSF=6mm时提取的峰度与无进展生存相关。

诊断标准与关键数值

  • SSF=4mm的峰度与总生存相关,HR为0.476(95%CI 0.29-0.77)。
  • SSF=6mm的峰度与无进展生存相关,HR为0.556(95%CI 0.36-0.86)。
  • 采用最佳截断值将患者分为高风险和低风险亚组。

临床应用与阅片要点

  • 作者认为CT直方图分析可能有助于接受纳武利尤单抗治疗的铂类难治性非小细胞肺癌患者的预后分层和治疗反应评估。

局限性

  • 原文在结论中自述「尽管存在局限性」,但摘要未具体列出局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The aim of this study was to assess computed-tomography histogram analysis (CTHA) as prognostic and predictive factor in platinum-refractory non-small cell lung carcinoma (NSCLC) treated with immune checkpoint inhibitor Nivolumab.

METHOD: One hundred and four patients were enrolled from 3 different centers. CT was performed using similar parameters among different scanners. CTHA was performed with the proprietary software TexRAD, which extracts histogram features at different spatial scale (spatial scale filters, SSF) producing 30 CTHA features per patients. Cross-validated Least Absolute Shrinkage and Selection Operator LASSO was used to select those features which were related to overall and progression-free survival (OS and PFS, respectively). High- and low-risk subgroups were identified using the best cutoff.

RESULTS: Median follow-up was 13.8 weeks. Median OS and PFS were 7.3 and 3 months, respectively. LASSO selected kurtosis obtained by SSF = 4 mm as the single feature related to OS, leading to an hazard ratio (HR) of 0.476 (95%CI 0.29-0.77). PFS was related with kurtosis SSF = 6 mm, with HR of 0.556 (95%CI 0.36-0.86).

CONCLUSION: Despite its limitations, this study is the first which suggests that CTHA could play a role in stratifying prognosis and treatment response in patients with NSCLC treated with Nivolumab.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ravanelli M, Agazzi GM, Milanese G, et al. Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study. Eur J Radiol. 2019. PMID: 31439251. doi:10.1016/j.ejrad.2019.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。